Novartis, Artios to develop cancer treatment

Wednesday, 07. April 2021 08:21

Artios Pharma Ltd. announced on Wednesday that it signed an agreement with Novartis International AG to develop new DNA Damage Response-based therapies for cancer.

According to the terms of the deal, the British company will receive an upfront payment of $20 million and is eligible for up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.

"This collaboration expands the reach of our discovery platform, leveraging our DDR expertise and target knowledge to enhance the potential of radioligand therapies. We are thrilled to work with Novartis, and this combined with our recent collaboration with Merck KGaA provides important validation of the power of the internal discovery capabilities at Artios," CEO Dr. Niall Martin stated in the press release.

Related Links: Novartis AG
Author:
Breaking the News / MD